GRI Bio Participates in a Virtual Investor CEO Connect Segment
GRI Bio (NASDAQ: GRI) announced its President and CEO Marc Hertz's participation in a Virtual Investor CEO Connect segment. During the presentation, Dr. Hertz discussed the company's lead program, GRI-0621, which targets Idiopathic Pulmonary Fibrosis (IPF), a rare chronic progressive fibrosing interstitial lung disease with treatment options.
The company highlighted upcoming milestones, including interim data expected at the beginning of next quarter and topline data in the subsequent quarter. The presentation is now available for viewing online through Virtual Investor's platform.
GRI Bio (NASDAQ: GRI) ha annunciato la partecipazione del suo Presidente e CEO, Marc Hertz, a un segmento Virtual Investor CEO Connect. Durante la presentazione, il Dr. Hertz ha discusso del programma principale dell'azienda, GRI-0621, che mira all'Fibrosi Polmonare Idiopatica (IPF), una rara malattia polmonare interstiziale fibrosante cronica progressiva con opzioni di trattamento disponibili.
L'azienda ha evidenziato i prossimi traguardi, inclusi i dati intermedi attesi all'inizio del prossimo trimestre e i dati principali nel trimestre successivo. La presentazione è ora disponibile per la visione online attraverso la piattaforma di Virtual Investor.
GRI Bio (NASDAQ: GRI) anunció la participación de su Presidente y CEO, Marc Hertz, en un segmento de Virtual Investor CEO Connect. Durante la presentación, el Dr. Hertz discutió sobre el programa principal de la compañía, GRI-0621, que se dirige a la Fibrosis Pulmonar Idiopática (IPF), una enfermedad pulmonar intersticial fibrosante crónica progresiva rara con opciones de tratamiento.
La empresa destacó los próximos hitos, incluidos los datos intermedios que se esperan a principios del próximo trimestre y los datos finales en el trimestre siguiente. La presentación ya está disponible para su visualización en línea a través de la plataforma de Virtual Investor.
GRI Bio (NASDAQ: GRI)는 사장 겸 CEO인 Marc Hertz가 Virtual Investor CEO Connect 세그먼트에 참여한다고 발표했습니다. 발표 중, Hertz 박사는 회사의 주요 프로그램인 GRI-0621에 대해 논의했으며, 이는 치료 옵션이 있는 드문 만성 진행성 섬유화 간질 폐질환인 특발성 폐섬유증 (IPF)을 목표로 하고 있습니다.
회사는 다음 분기 초에 예상되는 중간 데이터와 그 다음 분기에 제공될 주요 데이터를 포함한 향후 이정표를 강조했습니다. 발표 내용은 이제 Virtual Investor 플랫폼을 통해 온라인에서 시청할 수 있습니다.
GRI Bio (NASDAQ: GRI) a annoncé la participation de son Président et CEO, Marc Hertz, à un segment Virtual Investor CEO Connect. Lors de la présentation, Dr. Hertz a discuté du programme phare de l'entreprise, GRI-0621, qui cible la Fibrose Pulmonaire Idiopathique (IPF), une maladie pulmonaire interstitielle fibrosante chronique rare avec des options de traitement.
L'entreprise a mis en avant les prochaines étapes, y compris des données intermédiaires attendues au début du prochain trimestre et des données finales au trimestre suivant. La présentation est désormais disponible en ligne via la plateforme de Virtual Investor.
GRI Bio (NASDAQ: GRI) gab bekannt, dass sein Präsident und CEO, Marc Hertz, an einem Virtual Investor CEO Connect-Segment teilnehmen wird. Während der Präsentation sprach Dr. Hertz über das Hauptprogramm des Unternehmens, GRI-0621, das auf die Idiopathische Lungenfibrose (IPF) abzielt, eine seltene chronische fortschreitende fibrosierende interstitielle Lungenerkrankung mit verfügbaren Behandlungsoptionen.
Das Unternehmen hob bevorstehende Meilensteine hervor, darunter interimistische Daten, die zu Beginn des nächsten Quartals erwartet werden, und Hauptdaten im folgenden Quartal. Die Präsentation ist jetzt online über die Plattform von Virtual Investor verfügbar.
- Near-term catalysts with interim and topline data expected in coming quarters
- None.
Access the CEO Connect segment here
LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, President and CEO of GRI Bio participated in a Virtual Investor CEO Connect segment.
As part of this segment, Dr. Hertz provided an overview of GRI’s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in the following quarter.
The Virtual Investor CEO Connect featuring GRI Bio is now available here. Additional videos from the “What This Means” series are available on demand at https://virtualinvestorco.com/gri/.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing and effectiveness of the Reverse Split; the Company’s ability to regain compliance with the Nasdaq minimum bid price and other listing requirements; the Company’s expectations with respect to development and commercialization of the Company’s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
